李永文,缪 巍

胃癌是人体常见的恶性肿瘤根据五大洲肿瘤发病统计胃癌在80年代占各类恶性肿瘤首位。近些年由于肺癌发病率不断上升胃癌发病率退居第二位。

胃癌；免疫治疗；新型免疫联合疗法

[1] 孙秀娣,牧人,周有尚,戴旭东,张思维,皇甫小梅,孙杰,李连弟,鲁凤珠,乔友林,&孙(姓).中国胃癌死亡率20年变化情况分析及其发展趋势预测.中华肿瘤杂志2004年1月第26卷第1期Chin J Oncol‚ January2004‚ Vol26‚ No.1. [2] Parkin,D.M.,Bray,F.,Ferlay,J.&Pisani,P.Estimating the world cancer burden:Globocan 2000.Int.J.Cancer 94,153–156(2001). [3] International Agency for Research on Cancer-1994-Schistosomes,liver flukes and helicobacter pylori.pdf. [4] 李诚,周健.胃癌流行病学与分子生物学病因的研究进展.肿瘤防治研究2004年第31卷第2期. [5] Wang,R.et al.Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression.Cancer Cell 41, 1407-1426.e9(2023). [6] Chao,J.et al.Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059,KEYNOTE-061,and KEYNOTE-062 Clinical Trials.(2021). [7] Kang,Y.-K.et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial.The Lancet 390,2461–2471(2017). [8] Janjigian,Y.Y.et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction, and oesophageal adenocarcinoma(CheckMate 649):a randomised,open-label,phase 3 trial.The Lancet 398,27–40(2021). [9] Zhang,X.et al.Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer:New Strategies and Unveiled Opportunities.Front.Immunol.13,795972(2022). [10] Hossen,M.M.et al.Current understanding of CTLA-4:from mechanism to autoimmune diseases.Front.Immunol.14,1198365(2023). [11] Maleki Vareki,S.,Garrigós,C.&Duran,I.Biomarkers of response to PD-1/PD-L1 inhibition.Crit.Rev.Oncol.Hematol.116,116–124(2017).

点击下载PDF